Background
Salvage chemoimmunotherapy followed by autologous transplant (ASCT) was the second-line standard for relapsed large B-cell lymphoma (LBCL), but cured a minority of early-relapsing/refractory patients. ZUMA-7 tested upfront CAR-T (axicabtagene ciloleucel) versus standard salvage → ASCT.
Interventions and follow up
Arm A (SOC): Investigator-choice salvage chemoimmunotherapy (R-ICE, R-DHAP, or R-GDP, 2-3 cycles) → ASCT if responsive
Arm B: Axicabtagene ciloleucel (axi-cel, anti-CD19 CAR-T) single infusion 2 × 10⁶ cells/kg after lymphodepletion (fludarabine + cyclophosphamide)
Population: N=359, LBCL refractory or relapsed ≤12 months after 1L
Primary endpoint: event-free survival (EFS)
Median follow-up: 24.9 months (primary)
Arm B: Axicabtagene ciloleucel (axi-cel, anti-CD19 CAR-T) single infusion 2 × 10⁶ cells/kg after lymphodepletion (fludarabine + cyclophosphamide)
Population: N=359, LBCL refractory or relapsed ≤12 months after 1L
Primary endpoint: event-free survival (EFS)
Median follow-up: 24.9 months (primary)
Results
Median EFS: 8.3 vs 2.0 months (HR 0.40, 95% CI 0.31–0.51, P<.001)
Response: ORR 83% vs 50%; CR rate 65% vs 32%
4-yr OS (updated): 54.6% vs 46.0% (HR 0.73, 95% CI 0.54–0.98, P=.03)
Crossover/delivery: 94% of axi-cel patients infused; only 36% of SOC reached ASCT
Response: ORR 83% vs 50%; CR rate 65% vs 32%
4-yr OS (updated): 54.6% vs 46.0% (HR 0.73, 95% CI 0.54–0.98, P=.03)
Crossover/delivery: 94% of axi-cel patients infused; only 36% of SOC reached ASCT
Adverse events
CRS: any grade 92%, Grade ≥3 6%
ICANS/neurologic: any grade 60%, Grade ≥3 21%
Hematologic: prolonged Grade ≥3 cytopenias (neutropenia ~34% at day 30)
Other: ICU support required in ~25%; SOC arm dominated by myelosuppression from salvage chemo
ICANS/neurologic: any grade 60%, Grade ≥3 21%
Hematologic: prolonged Grade ≥3 cytopenias (neutropenia ~34% at day 30)
Other: ICU support required in ~25%; SOC arm dominated by myelosuppression from salvage chemo
Conclusions
Axi-cel significantly improved EFS, response, and ultimately OS over salvage + ASCT in second-line LBCL, establishing CAR-T as the preferred second-line therapy for primary refractory or early-relapsed disease.
Key Limitations
Only 36% of SOC patients reached ASCT, possibly inflating relative benefit; significant neurotoxicity (Grade ≥3 ICANS 21%); ICU resource needs limit community access; durable remissions still ~50%; CAR-T unavailable at many centers; limited bridging-therapy options on protocol; late relapses (>12 months) still benefit from salvage + ASCT.
Clinical Context
FDA approved axi-cel for 2L LBCL (refractory/relapse ≤12 months) in April 2022; EMA followed. With TRANSFORM (liso-cel), two CAR-T products have phase III support for 2L use. ASCO/ESMO guidance favors 2L CAR-T for primary refractory/early-relapse LBCL; late relapses still considered for salvage + ASCT.